Briclin

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Briclin
• 英文别名: 4-amino-N-[5-amino-2-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
• 化学式: C₂₂H₄₃N₅O₁₃
• 分子量: 585.6
• InChiKey: LKCWBDHBTVXHDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.9
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  332
• 氢给体数：
  13
• 氢受体数：
  17

文献信息

• Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
  申请人：Jalkanen Sirpa

  公开号：US20070093433A1

  公开（公告）日：2007-04-26

  The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.
• Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
  申请人：Malinin Vladimir

  公开号：US20100196455A1

  公开（公告）日：2010-08-05

  The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.
• COMPOSITIONS OF MULTICATIONIC DRUGS FOR REDUCING INTERACTIONS WITH POLYANIONIC BIOMOLECULES AND METHODS OF USE THEREOF
  申请人：Insmed Incorporated

  公开号：US20140248335A1

  公开（公告）日：2014-09-04

  The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.
• US9925205B2
  申请人：——

  公开号：US9925205B2

  公开（公告）日：2018-03-27